We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: December 8, 2011
Last Update Posted: March 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hoffmann-La Roche
This multi-center, prospective, observational study will describe the management of relapsing or refractory chronic lymphocytic leukemia (CLL) patients. Data will be collected for 2 years.

Lymphocytic Leukemia, Chronic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Non Interventional Study Aimed to Describe the Management of Relapse or Refractory Chronic Lymphocytic Leukemia (CLL) Patients Retreated by MabThera

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Chemotherapy regimens associated with MabThera/Rituxan in management of relapse/refractory CLL: Percentage of patients receiving purine analogues/bendamustine/alkylating agents/other chemotherapy [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Overall response rate [ Time Frame: 2 years ]
  • Complete response rate [ Time Frame: 2 years ]
  • Progression-free survival [ Time Frame: 2 years ]
  • Time to next treatment [ Time Frame: 2 years ]
  • Overall survival [ Time Frame: 2 years ]
  • Safety (incidence of adverse events) [ Time Frame: 2 years ]
  • Safety (incidence of hematologic adverse events) [ Time Frame: 2 years ]
  • Safety (incidence of infections) [ Time Frame: 2 years ]
  • Safety (incidence of secondary malignancies) [ Time Frame: 2 years ]

Enrollment: 327
Actual Study Start Date: April 4, 2011
Study Completion Date: October 24, 2016
Primary Completion Date: October 24, 2016 (Final data collection date for primary outcome measure)


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adult patients with relapsing or refractory chronic lymphocytic leukemia (CLL)

Inclusion Criteria:

  • Adult patients, >/=18 years of age
  • Diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) with first or second relapse
  • Previous treatment with MabThera/Rituxan
  • MabThera/Rituxan treatment planned for current relapse

Exclusion Criteria:

  • Richter syndrome
  • Life expectancy <6 months
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01488162

  Hide Study Locations
Aix En Provence, France, 13616
Aix En Provence, France, 13617
Albi, France, 81030
Angers, France, 49933
Antibes, France, 06600
Argenteuil, France, 95107
Arras, France, 62022
Avignon, France, 84902
Bayonne, France, 64109
Beziers, France, 34525
Beziers, France, 34535
Blois, France, 41016
Bobigny, France, 93009
Bordeaux, France, 33030
Bordeaux, France, 33077
Boulogne, France, 62321
Bourg En Bresse, France, 01012
Brest, France, 29609
Caen, France, 14033
Caen, France, 14076
Carcassonne, France, 11890
Castelnau Lez, France, 34170
Chalon Sur Saone, France, 71321
Chambery, France, 73011
Clermont Ferrand, France, 63003
Clermont Ferrand, France, 63050
Colmar, France, 68024
Compiegne, France, 60321
Corbeil Essonnes, France, 91000
Creil, France, 60109
Frejus, France, 83608
Grenoble, France, 38000
La Source, France, 45100
La Tronche, France, 38700
Le Mans, France, 72037
Libourne, France, 33505
Lyon, France, 69338
Macon, France, 71018
Marseille, France, 13005
Marseille, France, 13291
Melun, France, 77011
Metz Tessy, France, 74370
Metz, France, 57038
Metz, France, 57045
Montauban, France, 82013
Montpellier, France, 34295
Mulhouse, France, 68070
Nantes, France, 44093
Nantes, France, 44202
Nice, France, 06189
Nice, France, 06202
Nimes, France, 30029
Paris, France, 75181
Paris, France, 75475
Paris, France, 75571
Paris, France, 75651
Paris, France, 75679
Perpignan, France, 66012
Perpignan, France, 66046
Pessac, France, 33604
Pierre Benite, France, 69495
Poitiers, France, 86021
Pontoise, France, 95300
Reims, France, 51092
Rennes, France, 35000
Rennes, France, 35033
Roubaix, France, 59056
Rouen, France, 76038
Saint Herblain, France, 44805
Saint Quentin, France, 02321
Salon De Provence, France, 13658
Salouel, France, 80480
St Brieuc, France, 22027
St Germain En Laye, France, 78105
St Prient En Jarez, France, 42271
Strasbourg, France, 67091
Strasbourg, France, 67098
Toulon, France, 83041
Toulon, France, 83056
Toulouse, France, 31059
Tours, France, 37044
Troyes, France, 10003
Valence, France, 26953
Villejuif, France, 94804
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01488162     History of Changes
Other Study ID Numbers: ML25664
First Submitted: November 4, 2011
First Posted: December 8, 2011
Last Update Posted: March 22, 2017
Last Verified: March 2017

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents